Rhythm(RYTM) - 2024 Q3 - Quarterly Report

Sales Performance - IMCIVREE global sales revenue reached $33.3 million in Q3 2024, a 14$10.7 million to $33.3 million for the three months ended September 30, 2024, representing a 48$35.1 million to $88.3 million for the nine months ended September 30, 2024, representing a 66$185.8 million in product revenue since its approval in November 2020[160] Clinical Trials and Research - The Phase 3 pediatrics trial for setmelanotide showed a mean reduction of 3.04 in BMI-Z score and an 18.4% mean reduction in BMI among patients aged 2 to 6 with BBS or POMC/LEPR deficiencies[143] - The company has completed enrollment in its Phase 3 trial for acquired hypothalamic obesity and is advancing multiple clinical trials for new drug candidates RM-718 and bivamelagon (LB54640)[143] - Real-world data indicated that adult patients with acquired hypothalamic obesity achieved a mean BMI reduction of 12.8% at three months on setmelanotide therapy[147] - The Phase 2 DAYBREAK trial showed that 84% of patients on continuous setmelanotide therapy maintained a >5% BMI reduction over 40 weeks[148] - The company is leveraging a DNA database with nearly 80,000 sequencing samples to enhance understanding and treatment of severe obesity related to MC4R pathway variants[144] Financial Overview - As of September 30, 2024, the accumulated deficit was $1.1 billion, with a net loss of$43.6 million for the three months ended September 30, 2024[156] - Existing cash and cash equivalents and short-term investments were approximately $298.4 million as of September 30, 2024, expected to fund operations into 2026[157] - Net cash used in operating activities was$95.0 million for the nine months ended September 30, 2024, compared to $106.8 million in the same period in 2023[196][197] - Net cash provided by financing activities was$152.9 million for the nine months ended September 30, 2024, primarily from the issuance of Series A Preferred Stock[200] - The company raised approximately $791.5 million through common stock offerings since its IPO in October 2017, and$150 million from a recent investment agreement[152][153] Expenses and Cost Management - The cost of sales rose by $1.4 million to$3.8 million for the three months ended September 30, 2024, an increase of 59% driven by higher sales volume[178] - Research and development expenses increased by $4.4 million to$37.9 million for the three months ended September 30, 2024, a 13% increase from the same period in 2023[179] - Selling, general and administrative expenses increased by $4.9 million to$35.4 million for the three months ended September 30, 2024, reflecting a 16% increase compared to the same period in 2023[181] - Research and development expenses rose by $91.7 million to$196.8 million for the nine months ended September 30, 2024, an increase of 87% primarily due to acquired in-process research and development costs[187] - Selling, general, and administrative expenses increased by $21.0 million to$106.2 million for the nine months ended September 30, 2024, reflecting a 25% increase driven by higher salaries and marketing costs[190] Future Outlook and Funding - The company anticipates continued significant expenses and operating losses due to ongoing clinical trials and expansion of commercialization efforts[156] - The company expects to incur significant commercialization expenses related to product sales and marketing as it continues to develop its product candidates[202] - The existing cash and cash equivalents are expected to fund operations into 2026, but additional funding may be required for ongoing research and development activities[203][204] - The company expects to finance cash needs through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements due to the current economic volatility[207] - Future funding requirements may be impacted by economic conditions, including rising interest rates and declines in consumer confidence[207] Regulatory and Market Considerations - The FDA accepted the supplemental New Drug Application for IMCIVREE to treat children as young as 2 years old, with a PDUFA goal date set for December 26, 2024[150] - IMCIVREE was approved by the FDA and became commercially available in Q1 2021, but its commercial success remains uncertain[206] - The company may face dilution of stockholder ownership if additional capital is raised through equity or convertible debt securities[208] - The company may need to delay or limit product development if unable to raise additional funds through equity or debt financings[209] - The company has no material changes to its quantitative and qualitative disclosures about market risks as of September 30, 2024[214]